Who
John J. Crowley
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Centessa Pharmaceuticals; Chief Financial Officer, Fusion Pharmaceuticals; SVP, Chief Accounting Officer, Charles River Laboratories International.
In numbers
- Trades disclosed
- 63
- Buys
- 1
- Sells
- 3
- Bought
- $111K
- Sold
- $296K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Oct 2013
- Last trade
- 24 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 24 Jun 2026 | Centessa PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —600,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —250,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —600,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —250,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —181,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —181,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticals | SEC FORM 4 Code D | —45,000 | filing |
| 2 Feb 2026filed 3 Feb 2026 | Centessa PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —181,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —181,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | Centessa Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 Jul 2024filed 2 Jul 2024 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —38,561 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —26,972 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —60,852 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —138,000 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —167,000 | filing |
| 4 Jun 2024filed 4 Jun 2024 | Fusion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —250,000 | filing |
News
Charles River Laboratories International (NYSE:CRL) versus VivoSim Labs (NASDAQ:VIVS) Head-To-Head ContrastCRL · dailypolitical.com · 22 Oct 2026
0 headlines in the last 90 days name John J. Crowley; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.